Fisher R, Mandell G, Bostick F, McMenamin M, Anderson T
Clin Exp Immunol. 1980; 39(2):416-25.
PMID: 6446427
PMC: 1538078.
Lazarus P, Germina J, Dufour M, Palmer G, Wallace D, Panasci L
Cancer Chemother Pharmacol. 1983; 11(3):159-61.
PMID: 6227421
DOI: 10.1007/BF00254196.
Sava G, Giraldi T
Cancer Chemother Pharmacol. 1983; 10(3):167-9.
PMID: 6222844
DOI: 10.1007/BF00255754.
Fritsch A, Seidl W, WALZEL C, Moser K, Schiessel R
World J Surg. 1982; 6(5):569-77.
PMID: 6182702
DOI: 10.1007/BF01657871.
Lawton J, Giles G, Hall R, Bird G, Matheson T
Br J Surg. 1981; 68(6):397-9.
PMID: 6165425
PMC: 11428040.
DOI: 10.1002/bjs.1800680610.
Update in cancer chemotherapy: gastrointestinal cancer--colorectal cancer, Part 1.
Wright J
J Natl Med Assoc. 1986; 78(4):295-304.
PMID: 3712467
PMC: 2571283.
Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule.
Moriconi W, Taylor S, Slavik M, Belt R, Haas C, Hoogstraten B
Invest New Drugs. 1985; 3(1):57-62.
PMID: 3157661
DOI: 10.1007/BF00176825.
Antitumor activity of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-(4-methyl-cyclohexyl)-1-nitrosourea (MeCCNU) on Yoshida sarcoma ascites cells implanted into the colon wall of rats.
Bhide S, Habs M, Reinbold H, Schmahl D
J Cancer Res Clin Oncol. 1979; 94(1):63-7.
PMID: 468900
DOI: 10.1007/BF00405350.
Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin. I. Oncostatic effects in mice.
Hayat M, Bourut C, Chenu E, Montero J, Imbach J, Macdonald J
Cancer Chemother Pharmacol. 1979; 3(4):217-21.
PMID: 161207
DOI: 10.1007/BF00254734.
Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice.
Panasci L, Green D, Schein P
J Clin Invest. 1979; 64(4):1103-11.
PMID: 158033
PMC: 372222.
DOI: 10.1172/JCI109549.
